Marché mondial de la dystrophie musculaire facio-scapulo-humérale – Tendances et prévisions de l'industrie jusqu'en 2029

Analyse et perspectives du marché mondial de la dystrophie musculaire facio-scapulo-humérale

Le marché de la dystrophie musculaire facio-scapulo-humérale devrait connaître une croissance au cours de la période de prévision 2022-2029. Data Bridge Market Research analyse le marché pour s'attendre à une croissance à un TCAC de 4 % au cours de la période de prévision mentionnée ci-dessus.

La dystrophie musculaire facio-scapulo-humérale (FSHD) est une maladie musculaire génétique rare qui affecte le plus souvent les muscles du visage, des bras et des omoplates. La dystrophie musculaire est un trouble de dégénérescence musculaire progressive caractérisé par une faiblesse musculaire accrue et une atrophie (perte de masse musculaire). Le visage, les épaules et les bras sont les premiers muscles les plus gravement touchés par la FSHD, mais d'autres muscles sont généralement également touchés. La FSHD est causée par des mutations dans divers gènes (mutations). Dans la plupart des cellules du corps, un gène appelé DUX4 est inactif, mais dans la FSHD, il devient actif. Dans la FSHD de type 2, qui est moins fréquente, d'autres variables génétiques jouent un rôle. Les deux types produisent des problèmes de la même manière. Les garçons et les filles sont touchés par la FSHD. Elle peut être transmise à leurs enfants par l'un ou l'autre des parents. Il s'agit d'un modèle de transmission autosomique dominante. Chaque enfant d'un parent porteur du gène FSHD a une chance sur deux d'en hériter.

The rise in the number of patients suffering from facioscapulohumeral muscular dystrophy will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of facioscapulohumeral muscular dystrophy market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness about genetic disorders are the factors that will expand the facioscapulohumeral muscular dystrophy market. Other factors such as increasing adoption of early genetic counseling and favourable reimbursement policies will positively impact the facioscapulohumeral muscular dystrophy market’s growth rate. Additionally, high demand for effective treatment options and novel therapies will result in the expansion of facioscapulohumeral muscular dystrophy market.

Moreover, the rise in the research and development activities and launch of effective therapies will provide beneficial opportunities for the facioscapulohumeral muscular dystrophy market in the forecast period of 2022-2029. Also, ongoing clinical trials and strategic collaborations of leading manufacturers will escalate the growth rate facioscapulohumeral muscular dystrophy market in future.

However, high cost associated with the symptomatic treatment and lack of infrastructure in low-income countries will impede the growth rate of facioscapulohumeral muscular dystrophy market. Additionally, complications involved with facioscapulohumeral muscular dystrophy will hinder the facioscapulohumeral muscular dystrophy market growth. Less awareness about facioscapulohumeral muscular dystrophy and the lack of cure for this disease will further challenge the market in the forecast period mentioned above.

This facioscapulohumeral muscular dystrophy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the facioscapulohumeral muscular dystrophy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Facioscapulohumeral Muscular Dystrophy Market Scope and Market Size

The facioscapulohumeral muscular dystrophy market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of type, the facioscapulohumeral muscular dystrophy market is segmented into facioscapulohumeral muscular dystrophy 1 and facioscapulohumeral muscular dystrophy 2.
• On the basis of treatment, the facioscapulohumeral muscular dystrophy market is segmented into medication, physical therapy and others. The medication segment is further sub-segmented into non-steroidal anti-inflammatory drugs (NSAID) and others.
• On the basis of diagnosis, the facioscapulohumeral muscular dystrophy market is segmented into blood tests, magnetic resonance imaging (MRI), electromyography (EMG), genetic testing, DNA mutation analysis and others.
• On the basis of symptoms, the facioscapulohumeral muscular dystrophy market is segmented into muscle weakness, mild high-tone hearing loss, difficulty whistling, abnormalities, atrophy, lordosis and others.
• On the basis of dosage, the facioscapulohumeral muscular dystrophy market is segmented into injection, tablets and others.
• On the basis of route of administration, the facioscapulohumeral muscular dystrophy market is segmented into oral, parenteral and others.
• On the basis of end-users, the facioscapulohumeral muscular dystrophy market is segmented into clinic, hospital and others.

The facioscapulohumeral muscular dystrophy market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Facioscapulohumeral Muscular Dystrophy Market Country Level Analysis

Facioscapulohumeral muscular dystrophy market is analyzed and market size information is provided by the country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the facioscapulohumeral muscular dystrophy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the facioscapulohumeral muscular dystrophy market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Facioscapulohumeral muscular dystrophy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Facioscapulohumeral Muscular Dystrophy Market Share Analysis

Facioscapulohumeral muscular dystrophy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to facioscapulohumeral muscular dystrophy market research.

Some of the major players operating in the facioscapulohumeral muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Abbott, Bayer AG, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, AstraZeneca, Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Allergan, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, AbbVie Inc., Eli Lilly and Company, and Cipla Inc., among others.

Recent Development

En mai 2021, Fulcrum Therapeutics, Inc. a annoncé que la Food and Drug Administration (FDA) des États-Unis avait accordé une désignation accélérée au losmapimod pour le traitement potentiel de la dystrophie musculaire facio-scapulo-humérale (FSHD). Il n'existe actuellement aucun traitement approuvé pour la FSHD, et le losmapimod est le seul médicament en recherche clinique pour cette maladie importante et invalidante. Le losmapimod est développé pour répondre aux besoins médicaux non satisfaits des personnes atteintes de FSHD.

SKU-67514